CETILISTAT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H39NO3
Molecular Weight	401.5821
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C)C=C2)C(=O)O1

InChI

InChIKey=MVCQKIKWYUURMU-UHFFFAOYSA-N

InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C25H39NO3
Molecular Weight	401.5821
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16953261 | https://www.ncbi.nlm.nih.gov/pubmed/18393108

Cetilistat (ATL-962) is a pancreatic lipase inhibitor, which was developed by Alizyme plc, in collaboration with Takeda Pharmaceutical Co Ltd for the potential treatment of obesity in patients with or without diabetes. This drug was approved for using in Japan

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Pancreatic lipase 5 Target ID: CHEMBL1812 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18500680	Inhibitor 8297		5.95 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Obesity 203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24524093	Primary		Approved 8429	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Obesity drugs in clinical development.	2006 Apr	16625817
Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.	2007 Mar	16953261
Cetilistat, a new lipase inhibitor for the treatment of obesity.	2008 Apr	18393108
Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats.	2008 Aug	18500680
Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers.	2009 Mar	19220279
[Drug treatment of obesity--current situation and perspectives].	2010	21391349
Tackling obesity: new therapeutic agents for assisted weight loss.	2010 Apr 26	21437080
[Recent progress and novel perspectives on obesity pharmacotherapy].	2010 Aug	20857056
Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).	2010 Jan	19461584
The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents.	2010 May 10	21437083

Patents

Sample Use Guides

In Vivo Use Guide

60 mg three times daily t.i.d., 120 mg t.i.d. and 240 mg t.i.d.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:38:54 GMT 2023` Edited by `admin` on `Fri Dec 15 16:38:54 GMT 2023`
Record UNII	LC5G1JUA39
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CETILISTAT

Official Name

English

2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one

Systematic Name

English

ATL-962

Code

English

CETILISTAT [JAN]

Common Name

English

Cetilistat [WHO-DD]

Common Name

English

CETILISTAT [USAN]

Common Name

English

CETILISTAT [MI]

Common Name

English

cetilistat [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29715